Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer

Oct 23 2019

• By Mary Jo Laffler

Digital illustration of lung cancer cells in color background

Related Content

BMS Ready To Pounce On Non-Chemo Opportunity In Lung Cancer With Checkmate-227 Data

Jul 25 2019

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC

Sep 26 2018

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Jul 30 2018

AstraZeneca’s Imfinzi-Treme Checkpoint Inhibitor Combination Fails Again In NSCLC

Aug 21 2019

Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End

Aug 27 2019

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

Bristol Myers Squibb Company

AstraZeneca PLC

Additional Topics

Clinical Trials ImmunoOncology Research & Development Sales & Earnings Commercial Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.